Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd. is a Contract Development and Manufacturing Organization (CDMO) listed on the ChiNext board of the Shenzhen Stock Exchange since 2014. The company specializes in providing comprehensive services to pharmaceutical enterprises, biotech companies, and research institutions worldwide. It offers a range of CDMO services for various drug types, including small molecule drugs, large molecule drugs, and gene and cell therapies. The company operates across multiple business lines, including Small Molecule API CDMO, Small Molecule Drug Product CDMO, Gene and Cell Therapy CDMO, Synthetic Macromolecules CDMO, and Biological Macromolecules CDMO. Porton Pharma has established a global presence with over 20 operating sites in China, the United States, and Europe, and has successfully delivered more than 4,600 projects to over 1,300 clients. Its services span various therapeutic areas, including antivirals, oncology, and rare diseases, supported by a commitment to quality management and digital empowerment to enhance operational efficiency.

(1) A Global and End-to-End CDMO Platform to Meet Diverse Needs of Customers After 19 years of accumulation and evolution, the Company has established capabilities covering Small Molecule CDMO from starting materials to preparations, Synthetic Macromolecule CDMO such as peptides and oligonucleotides, Biological Macromolecule CDMO such as antibodies and ADCs, and Gene and Cell therapy CDMO, and provide a wide range of services from pre-clinical development through commercialization for different drugs and therapies. At the end of the reporting period, the Company has more than 20 Operating sites in China, the United States and Europe. The company's R&D technology platform is constantly maintaining its competitiveness through "faster innovation, centralized resources, improved efficiency, and keeping up with technological trends". Meanwhile, the Company's factory technology department has rich project experience and knowledge accumulation, and can provide professional services for customers to transfer projects from small-scale to commercialization. In addition, the Company also has professional engineering and technical capabilities to lay a solid foundation for building a highly flexible, internationally standardized manufacturing platform and improve manufacturing and operational efficiency. (2) Compliance Systems that Meet Global Standards, Overlaid with a Digital Empowerment Operating Management System The Company has established good reputation and delivery records in the industry, laying a solid foundation for the continuous development of new business. Our EHS management system, quality management system, as well as intellectual property and trade secret protection system are important cornerstones for the Company to maintain its leading position in the industry competition. Through digital empowerment, the Company proactively invests in quality reliability, cost optimization, engineering control, stable delivery, project management and other areas, to strengthen its core competitiveness. (3) Core Competitiveness as a ‘Pioneer’ Through 20 Years’ Experience in CDMO The Company provides services to hundreds of clients and projects each year. During the service process, the Company can engage deeply in the world's most advanced and complex pharmaceutical research and manufacturing, accumulating rich experience in the best practices and insights into the industry development. To date, the company has established business contacts with over 1,000 clients from the world's top 50 pharmaceutical companies, small and medium-sized pharmaceutical companies, and new drug development organizations of all types. Among the projects for which we have served, there are products that have been deeply bound for over ten years, potential reserve products that have been in service for two to three years, accompanying them from clinical phase one to phase two, and validation products obtained from customers due to technological advantages. Therefore, the Company has a relatively broad cooperation foundation, good delivery records, and brand image with global pharmaceutical companies and drug development organizations, which can provide more opportunities for the Company's future business development. (4) A Trustworthy Brand with the Corporate Culture of ‘Customer First, Pursuit of Excellence’ The Company has been implementing the service guidelines of ‘customer first, pursuit of excellence, constant innovation, and compliance’ in every customer service, constantly optimizing the customer experience. With more than 19 years of accumulation, the Company has established brand trust and influence among its major partners. In addition, the company continues to enhance market awareness and gain new customers' recognition through strengthening technology promotion.